stockrow
Monday 9 November 2026
Export STRO’s income statement to Excel — free account
Sutro Biopharma, Inc.
STROSutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024.
- Revenue
- −84.6%
- EPS
- −66.4%
- Free cash flow
- +14.6%
Quarter to June 2026, against a year earlier
9.62
0.42
+4.57%
Follow STRO
Alert me
Sutro Biopharma, Inc. (STRO) P/E ratio
Sutro Biopharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.6× (June 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.6×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. | n/m |
| INO Inovio Pharmaceuticals, Inc. compare | n/m |
| ORMP Oramed Pharmaceuticals Inc. compare | 0.9× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)